NEW YORK, NY / ACCESSWIRE / August 2, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Teladoc Health, Inc. (NYSE:TDOC)
Class Period: October 28, 2021 - April 27, 2022
Lead Plaintiff Deadline: August 5, 2022
During the class period, Teladoc Health, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) increased competition, among other factors, was negatively impacting Teladoc's BetterHelp and chronic care businesses; (ii) accordingly, the growth of those businesses was less sustainable than Defendants had led investors to believe; (iii) as a result, Teladoc's revenue and adjusted EBITDA projections for FY 2022 were unrealistic; (iv) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in TDOC: https://www.kleinstocklaw.com/pslra-1/teladoc-health-inc-loss-submission-form-2?id=30503&from=1
TG Therapeutics, Inc. (NASDAQ:TGTX)
Class Period: January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline: September 16, 2022
TG Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in TGTX: https://www.kleinstocklaw.com/pslra-1/tg-therapeutics-loss-submission-form?id=30503&from=1
Enochian BioSciences, Inc. (NASDAQ:ENOB)
Class Period: January 17, 2018 - June 27, 2022
Lead Plaintiff Deadline: September 26, 2022
The ENOB lawsuit alleges Enochian BioSciences, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in ENOB: https://www.kleinstocklaw.com/pslra-1/enochian-biosciences-inc-loss-submission-form?id=30503&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: